S. Valluri

发表

Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078.

M. Däumer, H. Valdez, A. Thielen, 2013, Antiviral research.

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study

J. McLaughlin, F. Xie, J. Slezak, 2022, The Lancet Respiratory Medicine.

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes

A. Luger, A. J. van der Lely, B. Biller, 2020, Frontiers in Endocrinology.

The maraviroc expanded access program — safety and efficacy data from an open-label study

A. Lazzarin, J. Molina, C. Craig, 2015, HIV clinical trials.

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study

O. A. Ogun, J. McLaughlin, K. Pan, 2022, The Lancet Regional Health - Americas.

Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study

L. Danon, N. Maskell, B. Gessner, 2022, The Lancet Regional Health - Europe.

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study

J. McLaughlin, B. Ackerson, V. Hong, 2022, The Lancet Respiratory Medicine.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

C. Fichtenbaum, H. Stellbrink, M. Saag, 2016, AIDS.

ALL-CAUSE MORTALITY IN PATIENTS WITH ACROMEGALY TREATED WITH PEGVISOMANT AN ACROSTUDY ANALYSIS.

A. Klibanski, N. Tritos, B. Biller, 2020, European journal of endocrinology.

Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program

A. Lazzarin, S. Than, J. Heera, 2012, HIV clinical trials.

First prospective comparison of genotypic versus phenotypic tropism assays in predicting virologic responses to maraviroc in a phase 3 study.

C. Craig, E. van der Ryst, J. Heera, 2019, The new microbiologica.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects

J. Marshall, P. Chan, S. Nepal, 2018, Journal of clinical pharmacology.

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants

J. Slezak, J. McLaughlin, B. Ackerson, 2022, The Lancet Respiratory Medicine.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

O. A. Ogun, F. Angulo, J. McLaughlin, 2021, The Lancet.

Systematic Review and Meta-analysis of Lyme Disease Data and Seropositivity for Borrelia burgdorferi, China, 2005‒2020

B. Gessner, K. Pan, R. Simon, 2022, Emerging infectious diseases.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY

M. Fleseriu, D. Führer-Sakel, A. J. van der Lely, 2021, European journal of endocrinology.

Results From an Open-Label Extension of the Phase 2 Dose Finding Study of Once Weekly Somatrogon vs Daily Genotropin in Pediatric Patients With Growth Hormone Deficiency (GHD)

N. Mauras, V. Iotova, R. Rosenfeld, 2021, Journal of the Endocrine Society.

Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (pGHD)

M. Phillip, C. Deal, C. Roland, 2021 .

An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment

N. Mauras, V. Iotova, Z. Zadik, 2023, Journal of pediatric endocrinology & metabolism : JPEM.

Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience

M. Fleseriu, R. Salvatori, T. Brue, 2022, Pituitary.

Assessing the Impact of Tiotropium on Lung Function and Physical Activity in GOLD Stage II COPD Patients who are Naïve to Maintenance Respiratory Therapy: A Study Protocol

F. Dobbels, I. Weisman, T. Troosters, 2011, The open respiratory medicine journal.

Physical inactivity in patients with COPD, a controlled multi-center pilot-study.

Thierry Troosters, Marc Decramer, Salvatore Battaglia, 2010, Respiratory medicine.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

J. McLaughlin, J. Slezak, B. Ackerson, 2022, SSRN Electronic Journal.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

J. McLaughlin, J. Slezak, B. Ackerson, 2022, SSRN Electronic Journal.

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

J. McLaughlin, B. Ackerson, V. Hong, 2022, JAMA network open.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

O. A. Ogun, F. Angulo, J. McLaughlin, 2021, SSRN Electronic Journal.

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study

D. Podzamczer, H. Valdez, M. Leal, 2013, Journal of acquired immune deficiency syndromes.

Safety and Pharmacokinetics of Nelfinavir During the Second and Third Trimesters of Pregnancy and Postpartum

P. Clax, A. Fang, T. Jones, 2012, HIV clinical trials.

OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial

C. Deal, J. Cara, S. Valluri, 2020, Journal of the Endocrine Society.

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study

M. Phillip, C. Deal, C. Roland, 2022, The Journal of clinical endocrinology and metabolism.

PDB4 Evaluation of Quality of Life in PRE-Pubertal Children Using the Quality of Life in Short Stature Youth (QOLISSY) Questionnaire, Following 12 Months of Growth Hormone Treatment with Either a Weekly Somatrogon or a Daily Genotropin Injection Schedule

J. Quitmann, S. Valluri, C. L. Roland, 2020 .

BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.

M. Falavigna, R. Rosa, E. D. de Souza, 2023, Vaccine.

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

C. Giaquinto, L. Mcfadyen, C. Craig, 2017, The Pediatric infectious disease journal.

Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.

O. A. Ogun, B. Ackerson, V. Hong, 2023, The Lancet. Respiratory medicine.

J. Quitmann, S. Valluri, Jane Loftus, 2023, Current medical research and opinion.

Maraviroc (MVC) increases CD4+ and CD8+ cells: long-term data from the MVC clinical development program

M. Battegay, A. Lazzarin, H. Valdez, 2010, Journal of the International AIDS Society.